---

Global Applications in 2007 Our premise is that low-dose oral interferon can be used efficaciously in most applications where high-dose injectable interferon currently is the approved therapy. The global market for high-dose injectable interferon alpha exceeds two billion dollars (U.S.) each year. Low-dose oral interferon, but not high-dose injectable interferon, can be afforded by most developing nations, and can represent growth beyond the projections of the current high-dose injectable interferon based market research. The indications for which high-dose injectable interferon is used are primarily mulitple sclerosis, hepatitis B and hepatitis C. There are several tumor types and cancers for which high-dose injectable interferon is used. There is also an approval for injection into genital warts. The high-dose injectable interferon has been used to treat Kaposi's Sarcoma in AIDS patients. Our premise is that low-dose oral interferon can be used efficaciously in each of these same indications, as well as others where high-dose injectable interferon currently is the approved therapy. The financial advantage from the diminished product costs of low-dose oral interferon, the handling, storage and personnel costs, combined with the much simplified logistics of administration make low-dose oral IFN a globally viable commercial therapeutic. Low-dose oral interferon simply has the ability to handle an economic void that high-dose injectable interferon will never be able to fill. This is a matter of economics interfaced with the health needs of our world.